In the present study, although the mean serum IGFBP2 level in gastric cancer patients was increased about 2-fold than that of healthy controls, its diagnostic sensitivity and specificity were only modest (79.7% and 64.7%, respectively), and it could not differentiate the cancer patients from controls statistically even at the optimal cut-off. Here, IGFBP2 is linked to cancer.